Redhill Biopharma Ltd
RDHL1.070USD
+0.040+3.88%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
3.56MMarktkapitalisierung
0.02KGV TTM
mehr Informationen über Redhill Biopharma Ltd Unternehmen
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd Informationen
BörsenkürzelRDHL
Name des UnternehmensRedhill Biopharma Ltd
IPO-datumFeb 01, 2011
CEOBen-Asher (Dror)
Anzahl der mitarbeiter35
WertpapierartDepository Receipt
GeschäftsjahresendeFeb 01
Addresse21 Ha'arba'a St.
StadtTEL AVIV-YAFO
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl6473921
Telefon97235413131
Websitehttps://www.redhillbio.com/
BörsenkürzelRDHL
IPO-datumFeb 01, 2011
CEOBen-Asher (Dror)
Führungskräfte von Redhill Biopharma Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 3
Aktualisiert: Sat, Jan 3
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Andere
99.46%
Aktionäre
Aktionäre
Anteil
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Andere
99.46%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
0.44%
Research Firm
0.07%
Investment Advisor
0.04%
Andere
99.45%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
36
28.22K
0.55%
-60.13K
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Gagnon Securities LLC
17.82K
0.35%
+17.82K
--
Sep 30, 2025
GAMMA Investing LLC
4.83K
0.09%
+4.69K
+3476.30%
Dec 31, 2025
Desjardins Securities Inc.
3.39K
0.07%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.03%
--
--
Sep 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Sep 30, 2025
EverSource Wealth Advisors, LLC
38.00
0%
+38.00
--
Sep 30, 2025
The Advocates
19.00
0%
+19.00
--
Sep 30, 2025
Rothschild Investment Corporation
17.00
0%
+17.00
--
Sep 30, 2025
UBS Switzerland AG
16.00
0%
+15.00
+1500.00%
Sep 30, 2025
Group One Trading, L.P.
11.00
0%
--
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
